The nuclear receptor PPARα α has been implicated in lipid and glucose homeostasis, although high affinity endogenous ligands have been elusive. The lipid oleylethanolamide has now been shown to be a true natural ligand for PPARα α, and to participate in the regulation of food intake and body weight.
peripherally. Other compounds affect appetite through both central and peripheral mechanisms. Cholecystokinin, for example, is a peptide secreted by the proximal small intestine in response to the ingestion of food, from whence it can act by direct stimulation of receptors in either the brain or the peripheral nervous system, specifically the vagus nerve [6] .
If the vagus nerve is cut or damaged by a drug such as capsaicin, cholecystokinin's ability to reduce food intake is reduced. Similar experiments have shown that peripheral afferent neurons are also important for the PPARα α has been implicated in variety of metabolic processes, although notably not in the regulation of food intake. It is expressed in a variety of tissues, but most prominently in liver, heart, kidney, muscle and brown adipose tissue [9] . It is involved in up-regulating genes that affect many of the pathways operating in the fasting state, such as gluconeogenesis, ketogenesis and fatty acid uptake and oxidation. In concordance with this, PPARα α null mice appear normal on a chow diet, but when fasted they become hypoglycemic, hypertriglyceridemic and hypoketonemic, with excess lipid stores in liver and other tissues [10, 11] . Interestingly, PPARα α null mice exhibit a non-significant decrease in food intake, an effect either neutral or in opposition to that predicted by the oleylethanolamide data [12] .
Endogenous high-affinity ligands have not previously been identified for any PPAR isoform. Despite this, several synthetic ligands of PPARα α were discovered empirically, and have been used clinically to reduce plasma lipid levels. These agents, collectively known as fibrates, have been shown to reduce body weight in obese rodent models, but until recently the effect had not been linked to reduced food intake [12] . Fu et al. Providing answers to these questions will keep researchers busy for a while, but ultimately the discovery of oleylethanolamide as a bona fide PPAR ligand is sure to spur the already intense race to discover other endogenous PPAR ligands. PPARγ γ in particular has been shown to have potent antidiabetic effects, and synthetic ligands are marketed for just that purpose. PPARγ γ also has anti-neoplastic and antiinflammatory effects [15] , and the discovery of novel chemicals that mediate these processes in vivo would be of enormous basic and therapeutic interest.
